5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1483
- Available Online
- View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Crohn Disease - drug therapy
- Colitis - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Colitis
- Abstract
- 5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Notes
- Previous title: 5-Aminosalicylate (5-ASA)
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1483
Adalimumab therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1207
- Available Online
- View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Adalimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Notes
- Previous title: Adalimumab (Humira) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1207
Corticosteroid therapy in inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35480
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1546
- Available Online
- View Pamphlet
Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Alternate Title
- Corticosteroid therapy in IBD
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Prednisone
- Subjects (LCSH)
- Inflammatory bowel diseases
- Prednisone
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Corticosteroids (kor-ti-koh-STER-oids) are strong inhibitors of inflammation (swelling). To ‘inhibit’ means to slow down or cut down on something. This pamphlet explains what corticosteriods do, how they work, when they are used, and how they are given. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Notes
- This pamphlet replaced pamphlet 1139, Prednisone Therapy.
- Responsibility
- Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Pamphlet Number
- 1546
Golimumab (Simponi®) for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35651
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1641
- Available Online
- View Pamphlet
Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (12 p.) : digital, PDF file
- Subjects (MeSH)
- Golimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your health care provider feels that treatment with golimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what golimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Notes
- Previous title: Golimumab (Simponi) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1641
Infliximab therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams34944
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1140
- Available Online
- View Pamphlet
Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (12 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Infliximab
- Subjects (LCSH)
- Inflammatory bowel diseases
- Infliximab
- Abstract
- Your health care provider feels that treatment with infliximab may help you to manage your inflammatory bowel disease (IBD). This pamphlet describes what infliximab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Notes
- Previous title: Infliximab (Remicade) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1140
